医保药品目录动态调整下药企应对策略——以A企业肺癌靶向药为例

Response of Drug Companies Under the Dynamic Adjustment of Medical Insurance Drug Catalogue——Taking Lung Cancer Targeted Drugs of Company A as an Example

目的:以A企业肺癌三代靶向药为例,分析药品企业应对医保药品目录动态调整的策略。方法:采用半结构化访谈法了解相关人员对医保政策调整的看法,通过问卷调查法了解患者用药满意度的变化,通过典型案例分析靶向药纳入医保目录前后的销售变化情况。结果:药品纳入医保目录后,药品价格显著下降,销售量显著上升,患者用药满意度明显提升。结论:企业应继续完善公司战略,加大创新研发力度,稳定药品质量和疗效,积极应对新一轮国家医保药品目录调整。

Objective:Taking Company A's third-generation targeted drugs for lung cancer as an example,the paper analyzed the strategies of drug companies to deal with the dynamic adjustment of the medical insurance drug catalogue.Methods:Semi-structured interview was used to understand the views of relevant personnel on the adjustment of medical insurance policy,the questionnaire survey was used to understand the changes in patients'satisfaction with medication,and typical cases were used to analyze the changes in the sales of targeted drugs before and after they were included in the medical insurance catalogue.Results:After drugs were included in the list of medical insurance,drug prices decreased significantly,drug sales increased significantly,and patients’satisfaction with drug increased significantly.Conclusions:Pharmaceutical enterprises should continue to improve corporate strategy,enhance innovation and research,stabilize drug quality and efficacy,and actively cope with a new round of adjustment of national medical insurance catalogue.